BR112021014566A2 - Moduladores de gpr35 - Google Patents

Moduladores de gpr35

Info

Publication number
BR112021014566A2
BR112021014566A2 BR112021014566A BR112021014566A BR112021014566A2 BR 112021014566 A2 BR112021014566 A2 BR 112021014566A2 BR 112021014566 A BR112021014566 A BR 112021014566A BR 112021014566 A BR112021014566 A BR 112021014566A BR 112021014566 A2 BR112021014566 A2 BR 112021014566A2
Authority
BR
Brazil
Prior art keywords
gpr35
modulators
compounds
gpr35 modulators
disorders
Prior art date
Application number
BR112021014566A
Other languages
English (en)
Inventor
Robert Higuchi
Original Assignee
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometheus Biosciences Inc filed Critical Prometheus Biosciences Inc
Publication of BR112021014566A2 publication Critical patent/BR112021014566A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Abstract

moduladores de gpr35. são descritos nesse relatório descritivo moduladores de gpr35 e métodos de utilização desses compostos no tratamento de doenças, distúrbios ou condições. também são descritas nesse relatório descritivo composições farmacêuticas que contêm esses compostos.
BR112021014566A 2019-01-24 2020-01-23 Moduladores de gpr35 BR112021014566A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962796459P 2019-01-24 2019-01-24
US201962873703P 2019-07-12 2019-07-12
US201962928223P 2019-10-30 2019-10-30
PCT/US2020/014777 WO2020154492A1 (en) 2019-01-24 2020-01-23 Gpr35 modulators

Publications (1)

Publication Number Publication Date
BR112021014566A2 true BR112021014566A2 (pt) 2022-01-04

Family

ID=71733100

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021014566A BR112021014566A2 (pt) 2019-01-24 2020-01-23 Moduladores de gpr35

Country Status (13)

Country Link
US (2) US11053251B2 (pt)
EP (1) EP3914256A4 (pt)
JP (1) JP2022518523A (pt)
KR (1) KR20210119485A (pt)
CN (1) CN113631168A (pt)
AU (1) AU2020210930A1 (pt)
BR (1) BR112021014566A2 (pt)
CA (1) CA3127786A1 (pt)
IL (1) IL285074A (pt)
MA (1) MA54825A (pt)
MX (1) MX2021008941A (pt)
TW (1) TW202043234A (pt)
WO (1) WO2020154492A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202043234A (zh) 2019-01-24 2020-12-01 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
TW202219047A (zh) * 2020-07-23 2022-05-16 美商普羅米修斯生物科學股份有限公司 靶向gpr35之治療劑

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1338235A (en) * 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
GB1421970A (en) * 1973-06-12 1976-01-21 May & Baker Ltd 8-azapurin-6-one derivatives
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4923874A (en) * 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
FR2845993B1 (fr) * 2002-10-16 2005-02-11 Univ Pasteur Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques
US20070287630A1 (en) 2006-06-12 2007-12-13 Driwater, Inc. Moisturizing agent with nutrients
AU2012262021B2 (en) * 2011-06-01 2016-07-28 Janus Biotherapeutics, Inc. Novel immune system modulators
EP3030682B1 (en) 2013-08-05 2020-06-03 Twist Bioscience Corporation De novo synthesized gene libraries
US20150273088A1 (en) * 2014-03-28 2015-10-01 Washington University Zaprinast analogues as glutaminase inhibitors and methods to predict response thereto
WO2016003901A1 (en) 2014-06-29 2016-01-07 Profile Products L.L.C. Bark and wood fiber growing medium
WO2018195328A1 (en) 2017-04-20 2018-10-25 Cedars-Sinai Medical Center Methods of predicting non-response to anti-tnf treatment in subjects with inflammatory bowel disease
WO2019210203A1 (en) 2018-04-27 2019-10-31 Cedars-Sinai Medical Center Compositions and methods of targeting gpr35 for the treatment of inflammatory bowel conditions
TW202043234A (zh) 2019-01-24 2020-12-01 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
CA3128942A1 (en) 2019-02-08 2020-08-13 Cedars-Sinai Medical Center Methods, systems, and kits for treating inflammatory disease targeting skap2
MX2021009247A (es) 2019-02-08 2021-09-08 Cedars Sinai Medical Center Metodos, sistemas y kits para tratar enfermedades inflamatorias que se dirigen a il18r1.
MX2021013974A (es) 2019-05-14 2022-02-10 Prometheus Biosciences Inc Metodos, sistemas y dispositivos de seleccion de pacientes tl1a.
EP4065727A4 (en) 2019-11-27 2024-03-27 Cedars Sinai Medical Center PREDICTION OF EXTRAINTESTINAL MANIFESTATIONS OF INFLAMMATORY BOWEL DISEASES
TW202219047A (zh) 2020-07-23 2022-05-16 美商普羅米修斯生物科學股份有限公司 靶向gpr35之治療劑
IL302791A (en) 2020-11-13 2023-07-01 Prometheus Biosciences Inc Methods, systems and kits for the treatment of TL1A-targeted inflammatory diseases
CA3202510A1 (en) 2020-12-21 2022-06-30 Dermot P. Mcgovern Tl1a therapy compositions and methods of treatment therewith

Also Published As

Publication number Publication date
CN113631168A (zh) 2021-11-09
US20200239476A1 (en) 2020-07-30
EP3914256A4 (en) 2022-09-28
KR20210119485A (ko) 2021-10-05
MX2021008941A (es) 2021-10-13
IL285074A (en) 2021-09-30
AU2020210930A1 (en) 2021-09-09
JP2022518523A (ja) 2022-03-15
US11773101B2 (en) 2023-10-03
US11053251B2 (en) 2021-07-06
WO2020154492A1 (en) 2020-07-30
TW202043234A (zh) 2020-12-01
MA54825A (fr) 2021-12-01
CA3127786A1 (en) 2020-07-30
EP3914256A1 (en) 2021-12-01
US20210380590A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
BR112019000692A2 (pt) moduladores de somatostatina e usos destes
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
AU2017261336A1 (en) Modulators of the integrated stress pathway
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
AU2017260374A1 (en) Modulators of the integrated stress pathway
EA201992083A1 (ru) Модуляторы соматостатина и их применения
BR112022002683A2 (pt) Agonistas não peptídicos do receptor de somatostatina tipo 5 e seus usos
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
BR112022000855A2 (pt) Moduladores de nlrp3
BR112019001921A2 (pt) moduladores do receptor nmda de espiro-lactama e seus usos
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
PH12019500949A1 (en) Ror-gamma modulators
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
BR112021022380A2 (pt) Inibidores de jak
CO2022014499A2 (es) Moduladores de nlrp3
BR112021014566A2 (pt) Moduladores de gpr35